Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis

Phase 4

Completed

Conditions: Ankylosing Spondylitis

Interventions: Drug: 150 mg open-label secukinumab
Drug: 150 mg double-blinded secukinumab
Drug: 300 mg double-blinded secukinumab

First Posted Date: 2017-11-22

Last Posted Date: 2022-04-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 322

Registration Number: NCT03350815

Locations: 🇺🇸
Novartis Investigative Site, Onalaska, Wisconsin, United States

Study of Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy

Phase 2

Completed

Conditions: Tendinopathy

Interventions: Other: Placebo
Drug: secukinumab

First Posted Date: 2017-11-17

Last Posted Date: 2021-10-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 96

Registration Number: NCT03344640

Locations: 🇬🇧
Novartis Investigative Site, Glasgow, United Kingdom

Dabrafenib and/or Trametinib Rollover Study

Phase 4

Recruiting

Conditions: Melanoma
Non Small Cell Lung Cancer
Solid Tumor
Rare Cancers
High Grade Glioma

Interventions: Drug: dabrafenib
Drug: trametinib

First Posted Date: 2017-11-13

Last Posted Date: 2025-04-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 100

Registration Number: NCT03340506

Locations: 🇺🇸
Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸
National Institute Of Health, Bethesda, Maryland, United States
🇺🇸
James Cancer Hospital and Solove Research Institute Ohio State, Columbus, Ohio, United States

and more 2 locations

Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH).

Phase 2

Completed

Conditions: Hemorrhagic Stroke
Intracerebral Hemorrhage (ICH)

Interventions: Drug: BAF312 solution
Drug: Matching Placebo for BAF312 solution
Drug: Matching Placebo for BAF312 tablet
Drug: BAF312 tablet

First Posted Date: 2017-11-09

Last Posted Date: 2022-08-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 32

Registration Number: NCT03338998

Locations: 🇺🇸
Novartis Investigative Site, Charlottesville, Virginia, United States

Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria.

Phase 2

Completed

Conditions: Malaria

Interventions: Drug: KAE609
Drug: Coartem

First Posted Date: 2017-11-07

Last Posted Date: 2021-10-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 188

Registration Number: NCT03334747

Locations: 🇺🇬
Novartis Investigative Site, Tororo, Uganda

Study on Safety, Tolerability and Prelimenary Efficacy of LNA043 in Patients Undergoing Autologous Chondrocyte Implantation

Phase 2

Terminated

Conditions: Knee Cartilage Lesion

Interventions: Biological: LNA043
Biological: placebo to LNA043

First Posted Date: 2017-11-07

Last Posted Date: 2021-10-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 14

Registration Number: NCT03334812

Locations: 🇦🇹
Novartis Investigative Site, Wien, Austria

Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis)

Phase 1

Terminated

Conditions: Cutaneous Squamous Cell Carcinoma in Situ (CSCCis)

Interventions: Drug: Placebo Cutaneous Cream application
Drug: Cutaneous Cream application

First Posted Date: 2017-11-07

Last Posted Date: 2020-12-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 40

Registration Number: NCT03333694

Locations: 🇧🇪
Novartis Investigative Site, Liege, Belgium

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Phase 1

Active, not recruiting

Conditions: EGFR-mutant Non-small Cell Lung Cancer

Interventions: Drug: EGF816
Drug: trametinib
Drug: LXH254
Drug: ribociclib
Drug: gefitinib
Drug: INC280

First Posted Date: 2017-11-06

Last Posted Date: 2025-05-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 105

Registration Number: NCT03333343

Locations: 🇨🇳
Novartis Investigative Site, Taipei, Taiwan

Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients

Phase 3

Completed

Conditions: Episodic Migraine

Interventions: Biological: Erenumab
Other: Placebo

First Posted Date: 2017-11-06

Last Posted Date: 2021-10-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 900

Registration Number: NCT03333109

Locations: 🇻🇳
Novartis Investigative Site, Hanoi, Vietnam

Study of Efficacy and Safety of Xolair® (Omalizumab) in Chinese Patients With Chronic Spontaneous Urticaria

Phase 3

Completed

Conditions: Chronic Spontaneous Urticaria

Interventions: Drug: Omalizumab
Drug: Placebo

First Posted Date: 2017-11-01

Last Posted Date: 2020-11-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 418

Registration Number: NCT03328897

Locations: 🇨🇳
Novartis Investigative Site, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy